1 | (-)-Epicatechin | 1件: Epicatechin Epicatechin | - | - | - | 2件: 86 86, 113 |
2 | (18F)FPGLU | - | - | - | - | 1件: 86 86 |
3 | (Pyr1)apelin-13 | - | - | - | - | 1件: 86 86 |
4 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 |
5 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 |
6 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 |
7 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
8 | 10-nitro-9(E)-octadec-9-enoic acid | - | - | - | - | 1件: 86 86 |
9 | 11C-ACETATE | 2件: Acetate Acetate, Acetic acid C-11 | - | - | - | 4件: 6 6, 13, 86, 88 |
10 | 120 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
11 | 129Xe Hyperpolarized | - | - | - | - | 1件: 86 86 |
12 | 15 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
13 | 150mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 |
14 | 171 | - | - | - | - | 1件: 86 86 |
15 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 |
16 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 |
17 | 20 mg sildenafil citrate by mouth | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
18 | 20 mg/ml Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
19 | 25% MTD sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
20 | 400 mg BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 |
21 | 45 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
22 | 4AU76 | - | - | - | - | 1件: 86 86 |
23 | 66215-101 | - | - | - | - | 1件: 86 86 |
24 | 6R-BH4 | 1件: Sapropterin Sapropterin | 1件: D08505
D08505
| - | - | 3件: 86 86, 124, 240 |
25 | 75mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 |
26 | 90 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
27 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 |
28 | [11C]-GSK2256098 500 MBq | 1件: GSK2256098 GSK2256098 | - | - | - | 1件: 86 86 |
29 | [18F] FES | - | - | - | - | 1件: 86 86 |
30 | [18F]Fluoro-2-deoxy-2-D-glucose | 1件: D-glucose D-glucose | 1件: D00009
D00009
| - | - | 2件: 86 86, 88 |
31 | Access program - sildenafil citrate, Viagra, Revatio | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
32 | ACE-011 | - | - | - | - | 1件: 86 86 |
33 | ACE-011 / MK - 7962 | - | - | - | - | 1件: 86 86 |
34 | ACE-011 / MK-7962 | - | - | - | - | 1件: 86 86 |
35 | ACE-011/ MK-7962 | - | - | - | - | 1件: 86 86 |
36 | Acetamide | 1件: Acetamide Acetamide | - | - | - | 2件: 86 86, 154 |
37 | Acetaminophen | 1件: Acetaminophen Acetaminophen | 1件: D00217
D00217
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 13件: 11 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337 |
38 | Acetate | 1件: Acetate Acetate | - | - | - | 41件: 1 1, 2, 6, 10, 13, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 171, 206, 222, 224, 225, 227, 235, 251, 265, 288, 298, 299 |
39 | ACT - 064992 | - | - | - | - | 1件: 86 86 |
40 | ACT-050089 | - | - | - | - | 1件: 86 86 |
41 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 |
42 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 |
43 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 |
44 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 |
45 | ACT-064992D | - | - | - | - | 1件: 86 86 |
46 | ACT-178418 | - | - | - | - | 1件: 86 86 |
47 | ACT-293987 | - | - | - | - | 3件: 51 51, 86, 88 |
48 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 |
49 | ACT-385781A | - | - | - | - | 1件: 86 86 |
50 | ACT-385781A (Actelion Epoprostenol) | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
51 | ActRIIA-IgG1Fc | - | - | - | - | 1件: 86 86 |
52 | Adcirca | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
53 | ADCIRCA 20 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
54 | Adcirca® | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
55 | Adempas | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 5件: 51 51, 86, 88, 225, 299 |
56 | Adempas (Riociguat, BAY63-2521) | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
57 | ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
58 | ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
59 | ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
60 | ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
61 | ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
62 | Adempas 0.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 |
63 | Adempas 0.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
64 | Adempas 1 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
65 | Adempas 1.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 |
66 | Adempas 1.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
67 | Adempas 1.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
68 | Adempas 2 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
69 | Adempas 2.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 |
70 | Adempas 2.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
71 | Adempas 2.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
72 | Adempas® | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
73 | Adempas® 0.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
74 | Adempas® 1.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
75 | Adempas® 1.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
76 | Adempas® 2.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
77 | Adempas® 2.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
78 | Adempas¿ 0.5 mg compressa rivestita con film | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
79 | Adempas¿ 1.0 | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
80 | Adempas¿ 1.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
81 | Adempas¿ 2.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
82 | Adempas¿ 2.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
83 | Adipose derived mesenchymal stem cells | - | - | - | - | 1件: 86 86 |
84 | AER-901 Solution for Nebulization | - | - | - | - | 1件: 86 86 |
85 | Aerosolized iloprost | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
86 | AIR001 | - | - | - | - | 1件: 86 86 |
87 | AIR001 (sodium nitrite inhalation solution) | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
88 | AIR001 Inhalation Solution | - | - | - | - | 1件: 86 86 |
89 | AIR001 Inhalation Solution (Expansion arm) | - | - | - | - | 1件: 86 86 |
90 | AL | - | - | - | - | 11件: 5 5, 6, 7, 13, 28, 51, 67, 86, 97, 114, 127 |
91 | Albuterol | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 7件: 12 12, 13, 86, 89, 113, 256, 299 |
92 | Albuterol. | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
93 | Allogeneic Human Cardiosphere-Derived Stem Cells | - | - | - | - | 1件: 86 86 |
94 | Ambrisentan | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 7件: 51 51, 84, 85, 86, 88, 210, 211 |
95 | Ambrisentan - high dose | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
96 | Ambrisentan - low dose | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
97 | Ambrisentan 5 mg film-coated tablets | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
98 | Ambrisentan 5mg film-coated tablets [marketed product] | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
99 | Ambrisentan plus Spironolactone | 2件: Ambrisentan Ambrisentan, Spironolactone | 2件: D00443
D00443
,
D07077
| 2件: EDNRA EDNRA, NR3C2 💬 | 8件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
100 | Ambrisentan Tablet | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
101 | AMN107 | - | - | - | - | 2件: 34 34, 86 |
102 | Anakinra | 1件: Anakinra Anakinra | 1件: D02934
D02934
| 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 16件: 2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299 |
103 | ANASTROZOLE | 1件: Anastrozole Anastrozole | 1件: D00960
D00960
| 1件: CYP19A1 CYP19A1 💬 | 3件: Metabolic pathways Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis 💬 | 3件: 78 78, 86, 193 |
104 | Angiotensin | 1件: Angiotensin II Angiotensin II | 2件: D00150
D00150
,
D02014
| 2件: AGTR1 AGTR1, AGTR2 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 7件: 17 17, 19, 46, 66, 86, 222, 224 |
105 | Apabetalone | 1件: Apabetalone Apabetalone | 1件: D11131
D11131
| 4件: BRD2 BRD2, BRD3, BRD4, BRDT 💬 | - | 1件: 86 86 |
106 | APD811 | - | - | - | - | 1件: 86 86 |
107 | Apelin | - | - | - | - | 1件: 86 86 |
108 | AR392830 | - | - | - | - | 1件: 86 86 |
109 | Aspirin | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 12件: 13 13, 22, 46, 49, 51, 58, 64, 86, 113, 158, 210, 231 |
110 | Assigned pulmonary hypertension medication | - | - | - | - | 1件: 86 86 |
111 | Autologous EPCs transfected | - | - | - | - | 1件: 86 86 |
112 | Autologous EPCs transfected with human eNOS | - | - | - | - | 1件: 86 86 |
113 | AV-101 | 1件: AV-101 AV-101 | - | - | - | 2件: 6 6, 86 |
114 | Aviptadil | 1件: Aviptadil Aviptadil | 1件: D12127
D12127
| - | - | 5件: 49 49, 51, 84, 85, 86 |
115 | AZD4831 | - | - | - | - | 1件: 86 86 |
116 | Background PAH Therapy | - | - | - | - | 1件: 86 86 |
117 | Bardoxolone | 1件: Bardoxolone Bardoxolone | 1件: D09584
D09584
| - | - | 7件: 66 66, 67, 84, 85, 86, 218, 222 |
118 | Bardoxolone methyl | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 7件: 66 66, 67, 84, 85, 86, 218, 222 |
119 | Bardoxolone methyl capsules | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 4件: 66 66, 67, 86, 222 |
120 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 86 86 |
121 | BAY 63-2521 | - | - | - | - | 2件: 86 86, 88 |
122 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 |
123 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 |
124 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 |
125 | BAY 63-2521 coated tablets 1 mg | - | - | - | - | 2件: 86 86, 88 |
126 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 |
127 | BAY 63-2521 coated tablets 2 mg | - | - | - | - | 2件: 86 86, 88 |
128 | BAY 63-2521 coated tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 |
129 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 |
130 | BAY 63-2521 IR tablets 1 mg | - | - | - | - | 1件: 86 86 |
131 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 |
132 | BAY 63-2521 IR tablets 1.5 mg | - | - | - | - | 1件: 86 86 |
133 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 |
134 | BAY 63-2521 IR tablets 2.5 mg | - | - | - | - | 1件: 86 86 |
135 | BAY 63-2521 Tablet | - | - | - | - | 1件: 86 86 |
136 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 |
137 | BAY 63-2521 tablets 1 mg | - | - | - | - | 2件: 86 86, 88 |
138 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 |
139 | BAY 63-2521 tablets 2 mg | - | - | - | - | 2件: 86 86, 88 |
140 | BAY 63-2521 tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 |
141 | Bay Q 6256 | - | - | - | - | 1件: 86 86 |
142 | BAY1237592 | - | - | - | - | 2件: 86 86, 88 |
143 | BAY63-2521 | - | - | - | - | 3件: 51 51, 86, 299 |
144 | Beetroot juice | - | - | - | - | 2件: 67 67, 86 |
145 | Benzbromaron | - | - | - | - | 1件: 86 86 |
146 | Benzbromaron AL | - | - | - | - | 1件: 86 86 |
147 | BENZBROMARONE | 1件: Benzbromarone Benzbromarone | 1件: D01056
D01056
| 1件: SLC22A12 SLC22A12 💬 | - | 1件: 86 86 |
148 | Beraprost | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
149 | Beraprost Sodium | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
150 | Beraprost Sodium 314d Modified Release Tablets | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
151 | Beraprost Sodium Modified Release | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
152 | BH4 | - | - | - | - | 5件: 51 51, 86, 124, 240, 299 |
153 | BIA | 1件: BIA BIA | - | - | - | 2件: 6 6, 86 |
154 | BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 |
155 | BIA-5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 |
156 | Biological DMARDs | - | - | - | - | 2件: 86 86, 107 |
157 | BISOPROLOL | 1件: Bisoprolol Bisoprolol | 1件: D02342
D02342
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 58 58, 67, 86, 113 |
158 | Bosentan | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 10件: 41 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
159 | Bosentan administration | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
160 | Bosentan and Sildenafil | 2件: Bosentan Bosentan, Sildenafil | 3件: D01227
D01227
,
D07538
,
D08514
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
161 | BOSENTAN MONOHIDRATO | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
162 | Bosentan monohydrat | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
163 | BOSENTAN MONOHYDRATE | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 84, 86, 88 |
164 | Bosentan, Ambrisentan | 2件: Ambrisentan Ambrisentan, Bosentan | 3件: D01227
D01227
,
D07077
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
165 | BPS-314d-MR | - | - | - | - | 1件: 86 86 |
166 | BPS-MR | - | - | - | - | 1件: 86 86 |
167 | Bromure d'Ipratropium | 1件: Ipratropium Ipratropium | - | - | - | 1件: 86 86 |
168 | BSF 208075 | - | - | - | - | 1件: 86 86 |
169 | BSF 208075 or LU 208075 | - | - | - | - | 1件: 86 86 |
170 | C07AB07 | - | - | - | - | 1件: 86 86 |
171 | C225 | - | - | - | - | 2件: 51 51, 86 |
172 | Capsaicin | 1件: Capsaicin Capsaicin | 1件: D00250
D00250
| 1件: TRPV1 TRPV1 💬 | 2件: Inflammatory mediator regulation of TRP channels Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 3件: 6 6, 86, 226 |
173 | Captopril | 1件: Captopril Captopril | 1件: D00251
D00251
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 2件: 17 17, 86 |
174 | Carbon | 1件: Activated charcoal Activated charcoal | - | - | - | 6件: 6 6, 85, 86, 96, 97, 158 |
175 | Carbon monoxide | 2件: Activated charcoal Activated charcoal, Carbon monoxide | 1件: D09706
D09706
| - | - | 2件: 85 85, 86 |
176 | Carnitine | 1件: Levocarnitine Levocarnitine | 1件: D02176
D02176
| - | - | 9件: 5 5, 13, 58, 86, 96, 97, 265, 298, 316 |
177 | Carvedilol | 1件: Carvedilol Carvedilol | 1件: D00255
D00255
| 5件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 💬 | 13件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 57 57, 86, 113, 210 |
178 | Cetuximab | 1件: Cetuximab Cetuximab | 1件: D03455
D03455
| 1件: EGFR EGFR 💬 | 48件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬 | 2件: 51 51, 86 |
179 | Chlorhexidine | 1件: Chlorhexidine Chlorhexidine | 1件: D07668
D07668
| - | - | 2件: 86 86, 299 |
180 | Cialis | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
181 | Cialis 10 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
182 | Cialis 2.5 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
183 | CIALIS 20 mg comprimidos recubiertos con película | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
184 | Cialis 20 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
185 | Cialis 5 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 |
186 | Cicletanine | 1件: Cicletanine Cicletanine | 1件: D03487
D03487
| - | - | 1件: 86 86 |
187 | Cicletanine hydrochloride | 1件: Cicletanine Cicletanine | 1件: D03487
D03487
| - | - | 1件: 86 86 |
188 | Citrulline | 1件: Citrulline Citrulline | - | - | - | 2件: 86 86, 113 |
189 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 |
190 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 |
191 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 |
192 | Clopidogrel | 1件: Clopidogrel Clopidogrel | 3件: D07729
D07729
,
D10823
,
D10824
| 1件: P2RY12 P2RY12 💬 | 1件: Platelet activation Platelet activation 💬 | 3件: 49 49, 51, 86 |
193 | Coenzyme Q-10 | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 1件: 86 86 |
194 | Coenzyme Q-10 in Normal Control subjects | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 1件: 86 86 |
195 | Coenzyme Q-10 in Pulmonary Hypertension subjects | 1件: Ubidecarenone Ubidecarenone | 1件: D01065
D01065
| - | - | 1件: 86 86 |
196 | Combination Product: | - | - | - | - | 1件: 86 86 |
197 | Combination Product: Implantable System for Remodulin (treprostinil) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
198 | Combination Product: Treprostinil via implanted pump | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
199 | Commercial Ventavis® (iloprost) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
200 | Conivaptan | 1件: Conivaptan Conivaptan | 1件: D07748
D07748
| 2件: AVPR1A AVPR1A, AVPR2 💬 | 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬 | 1件: 86 86 |
201 | Conventional drug therapy(expectorant,bronchodilator) | - | - | - | - | 1件: 86 86 |
202 | CosmoFer | - | - | - | - | 3件: 86 86, 96, 97 |
203 | CS1 Administration | - | - | - | - | 1件: 86 86 |
204 | Current marketed FLOLAN (epoprostenol sodium) | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
205 | CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 2件: 86 86, 222 |
206 | D-glucose | 1件: D-glucose D-glucose | 1件: D00009
D00009
| - | - | 3件: 49 49, 86, 88 |
207 | D.3.6.2 - dose massima specificare: giornaliera | - | - | - | - | 1件: 86 86 |
208 | Dapagliflozin | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 7件: 19 19, 49, 66, 67, 86, 88, 222 |
209 | Dapagliflozin 10 MG [Farxiga] | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
210 | DHEA | 1件: Prasterone Prasterone | 1件: D08409
D08409
| 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 3件: 49 49, 86, 96 |
211 | DHEA tablet | 1件: Prasterone Prasterone | 1件: D08409
D08409
| 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 86 86 |
212 | Dichloroacetate | 1件: Dichloroacetic acid Dichloroacetic acid | - | - | - | 1件: 86 86 |
213 | Dichloroacetate Sodium | 2件: Dichloroacetic acid Dichloroacetic acid, Sodium dichloroacetate | 1件: D05857
D05857
| 3件: PDK2 PDK2, PDK3, PDK4 💬 | 1件: Diabetic cardiomyopathy Diabetic cardiomyopathy 💬 | 1件: 86 86 |
214 | Diet | - | - | - | - | 4件: 86 86, 97, 240, 299 |
215 | Dietanolamina de treprostinilo | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
216 | Diltiazem | 1件: Diltiazem Diltiazem | 1件: D07845
D07845
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 58, 86 |
217 | Diltiazem Hydrochloride | 1件: Diltiazem Diltiazem | 1件: D07845
D07845
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
218 | DIMETHYL FUMARATE | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 4件: 13 13, 51, 86, 296 |
219 | Dimethyl Fumarate (DMF) | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 3件: 13 13, 51, 86 |
220 | Diphenhydramine | 1件: Diphenhydramine Diphenhydramine | 1件: D00300
D00300
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 8件: 11 11, 13, 49, 51, 70, 86, 222, 256 |
221 | Dobutamine | 1件: Dobutamine Dobutamine | 1件: D03879
D03879
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 57 57, 58, 86, 215 |
222 | Dobutamine test | 1件: Dobutamine Dobutamine | 1件: D03879
D03879
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
223 | Duo-Therapy with Sildenafil + Bosentan | 2件: Bosentan Bosentan, Sildenafil | 3件: D01227
D01227
,
D07538
,
D08514
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
224 | EFI/ACT-385781A | - | - | - | - | 1件: 86 86 |
225 | Elafin | 1件: Elafin Elafin | - | - | - | 1件: 86 86 |
226 | Endothelin receptor antagonist therapy | - | - | - | - | 1件: 86 86 |
227 | Endothelin Receptor Antagonists | - | - | - | - | 1件: 86 86 |
228 | Endothelin-3 | - | - | - | - | 1件: 86 86 |
229 | ENOS transfected EPCs will be delivered via a PA line | - | - | - | - | 1件: 86 86 |
230 | Epicatechin | 1件: Epicatechin Epicatechin | - | - | - | 2件: 86 86, 113 |
231 | EPOPROSTENOL | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
232 | Epoprostenol for injection | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
233 | EPOPROSTENOL SODICO | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
234 | EPOPROSTENOL SODIUM | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
235 | Epoprostenol-Actelion | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
236 | Epoprostenolo per iniezione | - | - | - | - | 1件: 86 86 |
237 | Equal | - | - | - | - | 4件: 6 6, 13, 67, 86 |
238 | ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) | 4件: Bosentan Bosentan, Macitentan, Sildenafil, Tadalafil | 5件: D01227
D01227
,
D02008
,
D07538
,
D08514
,
D10135
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
239 | ERA as specific PAH treatment | - | - | - | - | 1件: 86 86 |
240 | Erbitux | 1件: Cetuximab Cetuximab | 1件: D03455
D03455
| 1件: EGFR EGFR 💬 | 48件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬 | 2件: 51 51, 86 |
241 | Esomeprazole | 1件: Esomeprazole Esomeprazole | 1件: D07917
D07917
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
242 | ESR-specific PET scan | - | - | - | - | 1件: 86 86 |
243 | Esuberaprost | - | - | - | - | 1件: 86 86 |
244 | Eutonic Treprostinil Solution | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
245 | Famotidine | 1件: Famotidine Famotidine | 1件: D00318
D00318
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 5件: 6 6, 46, 86, 98, 107 |
246 | Famotidine 20 MG | 1件: Famotidine Famotidine | 1件: D00318
D00318
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 1件: 86 86 |
247 | FDC macitentan/tadalafil | 2件: Macitentan Macitentan, Tadalafil | 2件: D02008
D02008
,
D10135
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
248 | Ferinject | - | - | - | - | 2件: 86 86, 299 |
249 | Ferinject or CosmoFer | - | - | - | - | 1件: 86 86 |
250 | FERRIC CARBOXYMALTOSE | 1件: Ferric carboxymaltose Ferric carboxymaltose | 1件: D08920
D08920
| - | - | 4件: 86 86, 96, 97, 299 |
251 | Ferricarboxymaltose | - | - | - | - | 1件: 86 86 |
252 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 |
253 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 |
254 | FK506 level < 2 ng/ml | - | - | - | - | 1件: 86 86 |
255 | Flolan | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
256 | FLOLAN injection with currently marketed diluent | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
257 | FLOLAN injection with reformulated diluent | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
258 | FLOLAN TM and Glycine Diluent | 2件: Epoprostenol Epoprostenol, Glycine | 2件: D00011
D00011
,
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
259 | Flolan® | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
260 | FLOLAN™ and Glycine Diluent | 2件: Epoprostenol Epoprostenol, Glycine | 2件: D00011
D00011
,
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
261 | FLUOXETINE | 1件: Fluoxetine Fluoxetine | 1件: D00326
D00326
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 4件: 13 13, 17, 78, 86 |
262 | Forxiga | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
263 | Forxiga (dapagliflozin) | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
264 | Fulvestrant | 1件: Fulvestrant Fulvestrant | 1件: D01161
D01161
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 86 86 |
265 | Furosemide | 1件: Furosemide Furosemide | 1件: D00331
D00331
| 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 2件: 6 6, 86 |
266 | G04BE03 | - | - | - | - | 1件: 86 86 |
267 | G04BE03- Sildenafil - sildenafil (citrato) | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
268 | G04BE08 | - | - | - | - | 1件: 86 86 |
269 | GB002 | - | - | - | - | 1件: 86 86 |
270 | GB002 (seralutinib) | - | - | - | - | 1件: 86 86 |
271 | GB002 Capsules | - | - | - | - | 1件: 86 86 |
272 | GLIVEC | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 51 51, 86 |
273 | GLIVEC 100 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 34 34, 86 |
274 | Glivec 100 mg Filmtabletten | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 51 51, 86 |
275 | Glivec 100 mg Hartkapsel | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
276 | Glivec® | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
277 | Glivec® 100 mg Filmtabletten | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
278 | Glucose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 12件: 2 2, 6, 13, 49, 50, 66, 86, 88, 96, 97, 257, 299 |
279 | GLYCINE | 1件: Glycine Glycine | 1件: D00011
D00011
| - | - | 5件: 35 35, 60, 86, 226, 299 |
280 | GMA301 Injection | - | - | - | - | 1件: 86 86 |
281 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 |
282 | GS-4997 18 mg | - | - | - | - | 1件: 86 86 |
283 | GS-4997 2 mg | - | - | - | - | 1件: 86 86 |
284 | GS-4997 6 mg | - | - | - | - | 1件: 86 86 |
285 | GSK1325760 | - | - | - | - | 2件: 86 86, 88 |
286 | GSK1325760A | - | - | - | - | 1件: 86 86 |
287 | GSK2256098 | 1件: GSK2256098 GSK2256098 | - | - | - | 1件: 86 86 |
288 | GSK2586881 | - | - | - | - | 1件: 86 86 |
289 | HGP1206 | - | - | - | - | 1件: 86 86 |
290 | Hydroxyurea | 1件: Hydroxyurea Hydroxyurea | 1件: D00341
D00341
| 1件: RRM2 RRM2 💬 | 7件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway 💬 | 8件: 3 3, 13, 19, 20, 65, 85, 86, 284 |
291 | Hyperpolarized 129Xe | - | - | - | - | 1件: 86 86 |
292 | Hyperpolarized Xe129 | - | - | - | - | 4件: 51 51, 85, 86, 299 |
293 | HypotonicTreprostinil Solution | - | - | - | - | 1件: 86 86 |
294 | I.v. selexipag | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
295 | Ilomedin 20 | - | - | - | - | 1件: 86 86 |
296 | Ilomedin 20 [20 µg / ml] | - | - | - | - | 1件: 86 86 |
297 | Iloprost | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 4件: 51 51, 84, 85, 86 |
298 | Iloprost (5 µg) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
299 | Iloprost (Ventavis BAYQ6256) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
300 | Iloprost (Ventavis inhaled, BAYQ6256) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
301 | Iloprost (Ventavis, BAYQ 6256) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
302 | Iloprost (Ventavis, BAYQ6256) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
303 | Iloprost (Ventavis®) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
304 | Iloprost Inhalation Solution (Ventavis) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 85 85, 86 |
305 | Iloprost PD-15 | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
306 | Iloprost PD-6 | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
307 | Iloprost,(Ventavis, BAYQ6256) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
308 | Imatinib | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
309 | IMATINIB MESILATE | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 3件: 13 13, 86, 88 |
310 | Imatinib Mesylate | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 5件: 13 13, 28, 34, 51, 86 |
311 | Inhaled dry powder treprostinil (LIQ861) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
312 | Inhaled Iloprost (5 µg) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
313 | Inhaled iloprost (Ventavis, BAYQ6256) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
314 | Inhaled Nitric Oxide | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 2件: 85 85, 86 |
315 | Inhaled nitric oxide & INOpulse delivery | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 1件: 86 86 |
316 | Inhaled nitric oxide 75 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 2件: 85 85, 86 |
317 | Inhaled NO with pulsed delivery | - | - | - | - | 1件: 86 86 |
318 | Inhaled prostacyclin | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
319 | Inhaled Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 3件: 84 84, 85, 86 |
320 | INO | - | - | - | - | 2件: 85 85, 86 |
321 | Intestinal microbiota transplant (IMT) | - | - | - | - | 1件: 86 86 |
322 | Intravenous administration of ferric carboxymaltose | 1件: Ferric carboxymaltose Ferric carboxymaltose | 1件: D08920
D08920
| - | - | 1件: 86 86 |
323 | Intravenous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
324 | Ipratropium | 1件: Ipratropium Ipratropium | - | - | - | 2件: 6 6, 86 |
325 | Iron supplement | - | - | - | - | 1件: 86 86 |
326 | JNJ-67896049 | - | - | - | - | 1件: 86 86 |
327 | JNJ-67896049 (ACT-293987) | - | - | - | - | 1件: 86 86 |
328 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 |
329 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 |
330 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 |
331 | JTT-251 | - | - | - | - | 1件: 86 86 |
332 | KAR5585 Capsules | - | - | - | - | 1件: 86 86 |
333 | L-Carnitine | 1件: Levocarnitine Levocarnitine | 1件: D02176
D02176
| - | - | 7件: 13 13, 86, 96, 97, 265, 298, 316 |
334 | L-Citrulline Malate | 1件: Citrulline Citrulline | - | - | - | 1件: 86 86 |
335 | L606 (Liposomal Treprostinil) Inhalation Solution 51ug | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
336 | Levitra | 1件: Vardenafil Vardenafil | 1件: D08668
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 13 13, 86 |
337 | Lidocaine | 1件: Lidocaine Lidocaine | 2件: D00358
D00358
,
D08127
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 12件: 6 6, 13, 22, 34, 46, 51, 70, 86, 107, 168, 226, 256 |
338 | LIQ861 100 µg | - | - | - | - | 1件: 86 86 |
339 | LIQ861 106 µg | - | - | - | - | 1件: 86 86 |
340 | LIQ861 25 µg | - | - | - | - | 1件: 86 86 |
341 | LIQ861 26.5 µg | - | - | - | - | 1件: 86 86 |
342 | LIQ861 50 µg | - | - | - | - | 1件: 86 86 |
343 | LIQ861 53 µg | - | - | - | - | 1件: 86 86 |
344 | LIQ861 75 µg | - | - | - | - | 1件: 86 86 |
345 | LIQ861 79.5 µg | - | - | - | - | 1件: 86 86 |
346 | LIQ861 Inhaled Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
347 | LISURIDE | 1件: Lisuride Lisuride | 1件: D08132
D08132
| 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 2件: 6 6, 86 |
348 | Lloprost(Ventavis,BAYQ6252, 10 µg/mL) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
349 | Lloprost(Ventavis,BAYQ6252, 20 µg/mL) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
350 | LTP001 | - | - | - | - | 2件: 85 85, 86 |
351 | LY450190 | - | - | - | - | 1件: 86 86 |
352 | Macitentan | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 5件: 51 51, 85, 86, 88, 210 |
353 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
354 | Macitentan 10 mg | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 |
355 | Macitentan 10 mg tablet, once daily. | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
356 | Macitentan 37.5 mg | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
357 | Macitentan 75 mg | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
358 | MACITENTAN COMPRESSE | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
359 | Macitentan Group | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
360 | MACITENTAN TABLETS | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
361 | MD-711 | - | - | - | - | 1件: 86 86 |
362 | Medical air | 2件: Medical air Medical air, Oxygen | 1件: D00003
D00003
| - | - | 3件: 85 85, 86, 193 |
363 | Metformin | 1件: Metformin Metformin | 1件: D04966
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 25件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 |
364 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo | - | - | - | - | 1件: 86 86 |
365 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 |
366 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 |
367 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 46件: 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
368 | MK-4836 | - | - | - | - | 2件: 86 86, 88 |
369 | MK-5475 | - | - | - | - | 1件: 86 86 |
370 | MK-7962 | - | - | - | - | 1件: 86 86 |
371 | MK-8892 | - | - | - | - | 1件: 86 86 |
372 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 |
373 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 |
374 | Mono-Therapy with Sildenafil | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
375 | Morphine | 1件: Morphine Morphine | 1件: D08233
D08233
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 5件: 36 36, 46, 70, 85, 86 |
376 | MORPHINE SULFATE | 2件: Morphine Morphine, Sulfate ion | 1件: D08233
D08233
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 3件: 46 46, 85, 86 |
377 | Moxifloxacin | 1件: Moxifloxacin Moxifloxacin | 1件: D08237
D08237
| - | - | 9件: 2 2, 6, 46, 49, 85, 86, 113, 240, 299 |
378 | Moxifloxacin 400 mg | 1件: Moxifloxacin Moxifloxacin | 1件: D08237
D08237
| - | - | 1件: 86 86 |
379 | MultiHance | 1件: Gadobenic acid Gadobenic acid | 1件: D08018
D08018
| - | - | 2件: 86 86, 88 |
380 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 |
381 | Nebulized combination ipratropium bromide with salbutamol | 2件: Ipratropium Ipratropium, Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
382 | Nebulized ipratropium bromide | 1件: Ipratropium Ipratropium | - | - | - | 1件: 86 86 |
383 | New thermo stable formulation of epoprostenol sodium | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
384 | Nicardipine | 1件: Nicardipine Nicardipine | 1件: D08270
D08270
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 70 70, 86 |
385 | Nilotinib | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 5件: 6 6, 8, 34, 51, 86 |
386 | Nilotinib 50 mg | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
387 | NITRIC OXIDE | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 7件: 85 85, 86, 88, 210, 251, 294, 299 |
388 | Nitric Oxide for inhalation | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 2件: 86 86, 299 |
389 | Nitric Oxide generated by the GeNO nitrosyl delivery system | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 1件: 86 86 |
390 | Nitric Oxide plus Oxygen | 2件: Nitric Oxide Nitric Oxide, Oxygen | 2件: D00003
D00003
,
D00074
| - | - | 1件: 86 86 |
391 | Nitrite | 1件: Nitrite Nitrite | - | - | - | 2件: 58 58, 86 |
392 | Nitrosyl | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 1件: 86 86 |
393 | NO | - | - | - | - | 9件: 6 6, 46, 58, 62, 86, 97, 222, 299, 321 |
394 | Non-Biologic DMARDs | - | - | - | - | 3件: 46 46, 86, 107 |
395 | NS-304 | - | - | - | - | 3件: 70 70, 86, 88 |
396 | Null | - | - | - | - | 16件: 6 6, 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
397 | NX1011 | - | - | - | - | 1件: 86 86 |
398 | Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi | 4件: Epoprostenol Epoprostenol, Iloprost, Macitentan, Selexipag | 4件: D00106
D00106
,
D02721
,
D09994
,
D10135
| 3件: EDNRA EDNRA, EDNRB, PTGIR 💬 | 10件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
399 | Olaparib | 1件: Olaparib Olaparib | 1件: D09730
D09730
| 2件: PARP1 PARP1, PARP2 💬 | 5件: Apoptosis Apoptosis, Base excision repair, Diabetic cardiomyopathy, NF-kappa B signaling pathway, Necroptosis 💬 | 2件: 86 86, 285 |
400 | Opsumit | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 86 86, 88, 210 |
401 | Opsumit (macitentan) | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
402 | Opsumit® | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 86 86, 88, 210 |
403 | Oral anticoagulant treatment | - | - | - | - | 1件: 86 86 |
404 | Oral ERA | - | - | - | - | 1件: 86 86 |
405 | Oral PDE5 inhibitors | - | - | - | - | 1件: 86 86 |
406 | Oral selexipag (Uptravi) | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
407 | Oral sildenafil | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
408 | Oral treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 51 51, 86 |
409 | Oral treprostinil (UT-15C) Sustained Release Tablets | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
410 | Ossido Nitrico | - | - | - | - | 1件: 86 86 |
411 | Oxygen | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 13件: 6 6, 49, 70, 85, 86, 88, 90, 96, 168, 193, 271, 299, 330 |
412 | Oxygen supplementation | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 86 86 |
413 | Oxygen, liquid | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 2件: 86 86, 88 |
414 | PAH | - | - | - | - | 3件: 49 49, 53, 86 |
415 | PAH medication | - | - | - | - | 1件: 86 86 |
416 | PAH Therapies | - | - | - | - | 1件: 86 86 |
417 | Parenteral Remodulin (treprostinil) injection | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
418 | Parenteral Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
419 | PB1046 | - | - | - | - | 1件: 86 86 |
420 | PB1046 Subcutaneous Injection | - | - | - | - | 1件: 86 86 |
421 | PB1046, VIP-ELP1-120, Vasomera | - | - | - | - | 1件: 86 86 |
422 | PDE5 inhibitor | - | - | - | - | 1件: 86 86 |
423 | Pemziviptadil (PB1046) Injection | - | - | - | - | 1件: 86 86 |
424 | Pentoxifylline | 1件: Pentoxifylline Pentoxifylline | 1件: D00501
D00501
| - | - | 12件: 26 26, 56, 84, 86, 93, 96, 97, 113, 220, 222, 296, 298 |
425 | PF-00489791 | 1件: PF-00489791 PF-00489791 | - | - | - | 1件: 86 86 |
426 | Pioglitazone | 1件: Pioglitazone Pioglitazone | 1件: D08378
D08378
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
427 | Placebo | - | - | - | - | 28件: 3 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
428 | PLX-PAD | 1件: Placental Mesenchymal Stem Cells Placental Mesenchymal Stem Cells | - | - | - | 1件: 86 86 |
429 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 45件: 2 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
430 | Prostacyclin | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
431 | Prostacyclin Receptor Agonist | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
432 | Puri-Nethol | - | - | - | - | 3件: 86 86, 96, 97 |
433 | Q4W GMA301 IV injections (1000 mg) | - | - | - | - | 1件: 86 86 |
434 | Q4W GMA301 IV injections (300 mg) | - | - | - | - | 1件: 86 86 |
435 | Q4W GMA301 IV injections (600 mg) | - | - | - | - | 1件: 86 86 |
436 | QCC374 | - | - | - | - | 1件: 86 86 |
437 | QCC374 0.015 mg | - | - | - | - | 1件: 86 86 |
438 | QCC374 0.06 mg | - | - | - | - | 1件: 86 86 |
439 | QTI571 | - | - | - | - | 1件: 86 86 |
440 | Qutenza | - | - | - | - | 1件: 86 86 |
441 | Qutenza (8% capsaicin) | 1件: Capsaicin Capsaicin | 1件: D00250
D00250
| 1件: TRPV1 TRPV1 💬 | 2件: Inflammatory mediator regulation of TRP channels Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 86 86 |
442 | RALINEPAG | 1件: Ralinepag Ralinepag | 1件: D10725
D10725
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
443 | Ranolazine | 1件: Ranolazine Ranolazine | 1件: D05700
D05700
| - | - | 6件: 2 2, 58, 86, 96, 113, 114 |
444 | Rapamycin | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 18件: 15 15, 34, 35, 46, 49, 51, 53, 60, 61, 67, 86, 89, 96, 157, 158, 193, 256, 279 |
445 | Rapid Dose Titration Group of Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
446 | Recombinant Human Angiotensin-Converting Enzyme 2 | 2件: Alunacedase alfa Alunacedase alfa, Angiotensin II | 2件: D00150
D00150
,
D02014
| 2件: AGTR1 AGTR1, AGTR2 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
447 | Recombinant Human Angiotensin-converting enzyme 2 (ACE2), APN01 | 2件: Alunacedase alfa Alunacedase alfa, Angiotensin II | 2件: D00150
D00150
,
D02014
| 2件: AGTR1 AGTR1, AGTR2 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
448 | Remodulin | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 86 86, 88 |
449 | Remodulin (treprostinil sodium) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
450 | Remodulin® (treprostinil) 1 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
451 | Remodulin® (treprostinil) 10 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
452 | Remodulin® (treprostinil) 2.5 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
453 | Remodulin® (treprostinil) 5 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
454 | Revatio | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 3件: 85 85, 86, 113 |
455 | Revatio 10 mg/ml powder for oral suspension | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
456 | Revatio 20 mg film coated tablets | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
457 | Revatio 20 mg film-coated tablets | - | - | - | - | 1件: 86 86 |
458 | Revatio 20 mg Filmtabletten | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
459 | REVATIO 20 mg, comprimidos recubiertos con película | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
460 | Revatio inyectable | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
461 | Revatio oral | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
462 | Revatio POS | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
463 | Revatio Tablets | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
464 | Revatio ® 20 mg film-coated tablets | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
465 | Revatio® | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
466 | Riciguat Group | - | - | - | - | 1件: 86 86 |
467 | Rifampin | 1件: Rifampicin Rifampicin | 1件: D00211
D00211
| - | - | 5件: 6 6, 13, 84, 86, 299 |
468 | RIOCIGUAT | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 6件: 51 51, 84, 86, 88, 225, 299 |
469 | Riociguat (Adempas, BAY63-2521) | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 86, 88, 299 |
470 | Riociguat (BAY63-2521) | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
471 | Riociguat granules 0.3% for oral application | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
472 | Riociguat Oral Product | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
473 | Riociguat Oral Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 |
474 | Riociguat Pill | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
475 | Ritonavir | 1件: Ritonavir Ritonavir | 1件: D00427
D00427
| - | - | 3件: 2 2, 86, 265 |
476 | RITUXIMAB | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
477 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 |
478 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 |
479 | Ro-47-0203 | - | - | - | - | 1件: 86 86 |
480 | Ro-47-0203/029 | - | - | - | - | 1件: 86 86 |
481 | Ro47-0203 | - | - | - | - | 1件: 86 86 |
482 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 |
483 | RoActemra | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 11件: 40 40, 41, 44, 46, 50, 51, 86, 107, 266, 271, 331 |
484 | Rodatristat ethyl | - | - | - | - | 1件: 86 86 |
485 | Rodatristat ethyl 300 mg tablet BID | - | - | - | - | 1件: 86 86 |
486 | Rodatristat ethyl 600 mg BID | - | - | - | - | 1件: 86 86 |
487 | RT234 - vardenafil inhalation powder | 1件: Vardenafil Vardenafil | 1件: D08668
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
488 | RTA 402 | - | - | - | - | 3件: 67 67, 86, 218 |
489 | RVG 33865 | - | - | - | - | 1件: 86 86 |
490 | RVT-1201 | - | - | - | - | 1件: 86 86 |
491 | Salbutamol | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 8件: 3 3, 11, 49, 85, 86, 111, 256, 299 |
492 | Saline | - | - | - | - | 10件: 6 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
493 | Sapropterin | 1件: Sapropterin Sapropterin | 1件: D08505
D08505
| - | - | 3件: 86 86, 124, 240 |
494 | Sapropterin dihydrochloride (6R-BH4) | 1件: Sapropterin Sapropterin | 1件: D08505
D08505
| - | - | 1件: 86 86 |
495 | Saquinavir | 1件: Saquinavir Saquinavir | 1件: D00429
D00429
| - | - | 2件: 86 86, 265 |
496 | Saquinavir and ritonavir | 2件: Ritonavir Ritonavir, Saquinavir | 2件: D00427
D00427
,
D00429
| - | - | 1件: 86 86 |
497 | SATRALIZUMAB | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 11 11, 13, 86 |
498 | Satralizumab (Genetical Recombination) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 86 86 |
499 | Sauerstoff | - | - | - | - | 2件: 86 86, 88 |
500 | SELEXIPAG | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 5件: 51 51, 70, 84, 86, 88 |
501 | Selexipag (Uptravi) | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
502 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
503 | Selonsertib | 1件: Selonsertib Selonsertib | 1件: D10988
D10988
| 1件: MAP3K5 MAP3K5 💬 | 20件: Alcoholic liver disease Alcoholic liver disease, Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Huntington disease, Lipid and atherosclerosis, MAPK signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Protein processing in endoplasmic reticulum, Sphingolipid signaling pathway, Spinocerebellar ataxia, TNF signaling pathway, Thermogenesis, Tight junction 💬 | 1件: 86 86 |
504 | Seralutinib | - | - | - | - | 1件: 86 86 |
505 | Serine | 1件: Serine Serine | 1件: D00016
D00016
| - | - | 4件: 2 2, 6, 86, 96 |
506 | Sham O2 (medical air) | 2件: Medical air Medical air, Oxygen | 1件: D00003
D00003
| - | - | 1件: 86 86 |
507 | SILDENAF | - | - | - | - | 1件: 86 86 |
508 | Sildenafil | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
509 | Sildenafil (as citrate) | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
510 | Sildenafil (REVATIO) | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
511 | Sildenafil (Revatio) 20 mg TID | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
512 | Sildenafil 20mg | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
513 | Sildenafil 20mg and Bosentan 62.5mg | 2件: Bosentan Bosentan, Sildenafil | 3件: D01227
D01227
,
D07538
,
D08514
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
514 | Sildenafil citrate | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 85, 86, 225 |
515 | Sildenafil citrate (UK-92,480) | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
516 | Sildenafil Filmtabletten | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
517 | Sildenafil singly or in association with Bosentan | 2件: Bosentan Bosentan, Sildenafil | 3件: D01227
D01227
,
D07538
,
D08514
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
518 | SILDENAFILO | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
519 | Simvastatin | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 21件: 6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 |
520 | Simvastatin 40 mg | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 |
521 | Simvastatin 40 mg tablets | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 |
522 | Sirolimus | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 35件: 13 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 300, 331 |
523 | Sitaxentan | 1件: Sitaxentan Sitaxentan | 1件: D07171
D07171
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
524 | Sitaxentan sodium | 1件: Sitaxentan Sitaxentan | 1件: D07171
D07171
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
525 | Sitaxsentan | 1件: Sitaxentan Sitaxentan | 1件: D07171
D07171
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
526 | Sitaxsentan alone | 1件: Sitaxentan Sitaxentan | 1件: D07171
D07171
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
527 | Sitaxsentan and Sildenafil | 2件: Sildenafil Sildenafil, Sitaxentan | 2件: D07171
D07171
,
D08514
| 2件: EDNRA EDNRA, PDE5A 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
528 | SITAXSENTAN SODIUM | 1件: Sitaxentan Sitaxentan | 1件: D07171
D07171
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
529 | Slow Dose Titration Group of Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
530 | SODIUM NITRITE | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
531 | Sodium Nitrite Inhalation Solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 |
532 | Sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth | 2件: Dextrose, unspecified form Dextrose, unspecified form, Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
533 | Sorafenib | 1件: Sorafenib Sorafenib | 1件: D08524
D08524
| 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 2件: 34 34, 86 |
534 | SOTATERCEPT | 1件: Sotatercept Sotatercept | 1件: D09670
D09670
| 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 2件: 86 86, 284 |
535 | Sotatercept - 45 mg/vial | 1件: Sotatercept Sotatercept | 1件: D09670
D09670
| 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 |
536 | Sotatercept - 60 mg/vial | 1件: Sotatercept Sotatercept | 1件: D09670
D09670
| 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 |
537 | Spironolactone | 1件: Spironolactone Spironolactone | 1件: D00443
D00443
| 1件: NR3C2 NR3C2 💬 | 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption 💬 | 8件: 46 46, 58, 67, 86, 113, 210, 218, 225 |
538 | Spironolactone and conivaptan | 2件: Conivaptan Conivaptan, Spironolactone | 2件: D00443
D00443
,
D07748
| 3件: AVPR1A AVPR1A, AVPR2, NR3C2 💬 | 6件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬 | 1件: 86 86 |
539 | Spironolactone captopril carvedilol | 3件: Captopril Captopril, Carvedilol, Spironolactone | 3件: D00251
D00251
,
D00255
,
D00443
| 7件: ACE ACE, ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, NR3C2 💬 | 19件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Chemical carcinogenesis - receptor activation, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
540 | STI571 | - | - | - | - | 2件: 51 51, 86 |
541 | Subcutaneous and intravenous prostacyclin | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
542 | Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
543 | Sugar pill | - | - | - | - | 8件: 5 5, 6, 49, 67, 70, 86, 206, 210 |
544 | SULFASALAZINE | 1件: Sulfasalazine Sulfasalazine | 1件: D00448
D00448
| - | - | 6件: 46 46, 86, 94, 107, 270, 271 |
545 | Sulfate | 1件: Sulfate ion Sulfate ion | - | - | - | 27件: 2 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 85, 86, 96, 111, 218, 222, 224, 226, 265, 296, 297, 299 |
546 | Tadalafil | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 7件: 6 6, 51, 75, 84, 86, 113, 210 |
547 | Tadalafil 20 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
548 | Tadalafil 40 mg | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
549 | Tadalafil and ambrisentan upfront combination therapy | 2件: Ambrisentan Ambrisentan, Tadalafil | 2件: D02008
D02008
,
D07077
| 2件: EDNRA EDNRA, PDE5A 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 |
550 | Tadalafil oral suspension | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
551 | Tadalafil- Tablet or Oral suspension | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
552 | TADALAFILO | 1件: Tadalafil Tadalafil | 1件: D02008
D02008
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
553 | Tasigna | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 34 34, 86 |
554 | Tasigna® | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
555 | Tasigna® 150 mg | 1件: Nilotinib Nilotinib | 1件: D08953
D08953
| 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
556 | TBD | - | - | - | - | 5件: 19 19, 86, 90, 276, 299 |
557 | Tegaderm | - | - | - | - | 1件: 86 86 |
558 | Terguride | 1件: Terguride Terguride | 1件: D01348
D01348
| 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, |